Navigation Links
Amgen and Micromet Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Micromet
Date:2/15/2012

THOUSAND OAKS, Calif., Feb. 15, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Micromet, Inc. (NASDAQ: MITI) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (HSR), in connection with Amgen's tender offer for Micromet, was terminated early on Feb. 14, 2012 by the U.S. Federal Trade Commission.  The waiting period was scheduled to expire on Feb. 17, 2012.     

As previously announced on Jan. 26, 2012, Amgen and Micromet entered into a Merger Agreement contemplating the acquisition of Micromet by Amgen via a tender offer to acquire all of the outstanding shares of Micromet's common stock at a price of $11 per share in cash.  The termination of the HSR waiting period satisfies one of the conditions to consummate the tender offer.  Other closing conditions remain to be satisfied, including, among others, a minimum tender of at least a majority of outstanding Micromet shares on a fully diluted basis.

The tender offer will remain open for Micromet stockholders to tender their shares until 12:00 midnight, New York City time, at the end of Thursday, March 1, 2012, unless it is extended pursuant to and in accordance with the terms of the Merger Agreement.  The complete Offer to Purchase dated Feb. 2, 2012 related to the tender offer has been filed with the U.S. Securities and Exchange Commission and can be viewed online at www.sec.gov

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
(Date:8/19/2014)... BIRMINGHAM, Ala. , Aug. 19, 2014  The Alabama ... re-affirmed that patients can sue drug makers who mislead doctors ... cause harmful side‑effects.  The case is Weeks v. Wyeth, and ... drug makers in that same case last year. Heninger Garrison ... represent the patient in the case, Danny Weeks ...
(Date:8/19/2014)... -- Minimally Invasive Devices Inc. (MID), a ... that Mitsubishi Corporation has formally agreed to exclusively distribute ... Japan . MID anticipates that FloShield will ... in the second half of 2015. ... Storz GMBH & Co. (endoscopic instruments and devices) in ...
Breaking Medicine Technology:Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2
... achieve undetectable viral load in Phase,IIa trial within ... care, SAN FRANCISCO, Nov. 1 New ... protease inhibitor (PI) being,developed by Tibotec BVBA for ... Tibotec will present findings from three TMC435 studies,including ...
... Higher Sustained Virological Response Rates Recognized as Marker ... 1 A new,independently-conducted study being presented at ... the Study of Liver Diseases (AASLD) shows that,PEGASYS(R) ... response (SVR) rates for hepatitis C patients as,compared ...
Cached Medicine Technology:Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 2Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 3Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 4Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7
(Date:8/20/2014)... August 20, 2014 Doctors at the University ... wipe out mesothelioma in laboratory mice by injecting them with ... posted details of the study on its website. Click ... with Hong Kong University’s AIDS Institute of Microbiology created a ... or PD-1. By altering DNA, the vaccine is designed to ...
(Date:8/20/2014)... Today, Zane Benefits, the #1 Online ... for 2015. , According to Zane Benefits, with open ... employees are encouraged to start thinking about their healthcare ... open enrollment period will run from November 15, 2014 ... can purchase a new individual health insurance policy, or ...
(Date:8/20/2014)... 20, 2014 The report “Automotive ... - A Global Analysis: by Geography - Trends ... classifies and defines automotive airbag and seatbelt market ... highlights potential growth opportunities in the coming years ... market drivers, restrains, growth indicators, challenges, legislation trends, ...
(Date:8/20/2014)... August 20, 2014 In a recent ... a University College London (UCL) study showed that dental ... method of brushing teeth was the most effective. Analysis ... different tooth-brushing techniques were frequently recommended, but none were ... for Cosmetic Dentistry, experienced cosmetic dentist Dr. ...
(Date:8/20/2014)... Hope For The Warriors® is excited to announce ... in Washington, DC on Thursday, October 2, 2014 at ... the courage of our wounded service members, their families, ... Got Heart, Give Hope® Celebration will benefit Hope For ... sense of self, restoring the family unit, and restoring ...
Breaking Medicine News(10 mins):Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2
... May 19 Towards the Electronic,Patient Record ... interface terminology,announced today its next-generation interface terminology ... terminologies access to all of,IMO,s terminology knowledge ... algorithms optimized for millisecond response times in ...
... Sciences (OTC,Bulletin Board: DSCI), a provider of advanced ... Burn Dressing, its flagship wound care,product, was profiled ... Reporter Lisa Thomas-Laury examines the use of ... Leonard Abrams Center for Advanced Wound,Healing of the ...
... Health, Inc., one of,the nation,s largest public/private health ... provider of software agent,technologies for health information exchange, ... clinicians at the point of care., Shared ... the clinical,interface capabilities of what is already one ...
... Should Be ,Wake-Up Call, for Doctors and Women, WASHINGTON, ... coronary artery disease are significantly less likely than,men to be ... WomenHeart - the national coalition for women with heart,disease -- ... sure,that women are getting the care that they need., ...
... May 19 Edifecs, the leader in ... EDS has,selected the Edifecs Healthcare Accelerator Suite ... health care transactions in both,real-time and batch ... of the,EDS MetaVance(R) Administration and Finance System., ...
... of Liverpool has performed a groundbreaking operation on a chimp ... dogs. , The three year-old chimp called Janet was rescued ... in a chimpanzee reserve supported by the Cameroon Wildlife Aid ... because a bone in her forearm - the ulna - ...
Cached Medicine News:Health News:Intelligent Medical Objects (IMO), Inc. announces the General Availability of Its Terminology Portal Service for EMR/EHR and Charge-Capture Applications 2Health News:Intelligent Medical Objects (IMO), Inc. announces the General Availability of Its Terminology Portal Service for EMR/EHR and Charge-Capture Applications 3Health News:Intelligent Medical Objects (IMO), Inc. announces the General Availability of Its Terminology Portal Service for EMR/EHR and Charge-Capture Applications 4Health News:Derma Sciences' MEDIHONEY(TM) Profiled By ABC News' Philadelphia Affiliate 2Health News:Shared Health(R) and Novo Innovations Partner for Improved Information-Sharing of Clinical Health Records 2Health News:Shared Health(R) and Novo Innovations Partner for Improved Information-Sharing of Clinical Health Records 3Health News:Study: Doctors Significantly Less Likely to Provide Women with Treatments to Prevent Heart Attacks 2Health News:EDS Selects Edifecs Healthcare Accelerator Suite for Claims Processing Solution 2Health News:Surgeon operates to rescue chimp with rare deformity 2
... and model 1488 active-fixation leads are among ... the unsurpassed handling advantages, performance, and reliability ... active-fixation leads. Implantable with a 7 F ... Tendril SDX lead is designed to lower ...
... CheckPoint is an automated, wireless, computerized ... alert system for refrigerator, freezer, incubator ... recorders, data loggers and manual temperature ... an existing PC and comes complete ...
... This requiring no water for ... hand hygiene to physically clean ... is either not an option ... allows you to return to ...
BioSoft alcohol gel hand antiseptic with soothing moisturizers is a fast-acting, broad-spectrum antimicrobial solution. BioSoft alcohol gel hand antiseptic applies easily, requires no rinsing and dri...
Medicine Products: